Maleic Acid

Maleic Acid

SCHEMBL5094863

CN(C)CCc1c2n(c3ccc(F)cc13)C(=O)c1ccccc1-2.O=C(O)/C=C\C(=O)O

nearest known ligand 0.42

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2BTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3MPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PPARGSLC6A2SLC6A3SLC6A4SMOTYK2pol

The experimentally established mechanism targets of Maleic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR1A known ✓ P08908 1/20 0.38
▸ ADRA2A known ✓ P08913 1/20 0.38
▸ ADRA2B known ✓ P18089 1/20 0.38
▸ ADRA2C known ✓ P18825 1/20 0.38
▸ ADRA1D known ✓ P25100 1/20 0.38
▸ HTR2A known ✓ P28223 1/20 0.38
▸ HTR2C known ✓ P28335 1/20 0.38
▸ ADRA1A known ✓ P35348 1/20 0.38
▸ HRH1 known ✓ P35367 1/20 0.38
▸ ADRA1B known ✓ P35368 1/20 0.38
▸ HTR2B known ✓ P41595 1/20 0.38
▸ TACR1 P25103 1/20 0.42
▸ HTR7 P34969 5/20 0.41
▸ HTR6 P50406 4/20 0.39
▸ MAOA P21397 1/20 0.38
▸ HTR1B P28222 1/20 0.38
▸ CHRNB4 P30926 1/20 0.38
▸ CHRNA3 P32297 1/20 0.38
▸ HTR5A P47898 1/20 0.38
▸ PADI4 Q9UM07 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Oxalic Acid SCHEMBL5094982 0.93 TACR1 (0.43) TACR1HTR7HTR6HTR1AHTR1B
SCHEMBL5094690 0.92 HTR6 (0.44) TACR1HTR6MAPTPTGDR2PTGDR
Hydrochloric Acid SCHEMBL5094866 0.91 HTR6 (0.43) TACR1HTR6MAPTPTGDR2PTGDR
Citric Acid SCHEMBL5101053 0.86 TACR1 (0.41) TACR1HTR6PTGDR2PTGDRPTGIR
SCHEMBL5095599 0.80 TACR1 (0.41) TACR1HTR6HRH1PTGDR2PTGDR
SCHEMBL5094719 0.80 TACR1 (0.52) TACR1HTR7HTR6HTR1AHTR2A
SCHEMBL5101411 0.79 RXRA (0.45) TACR1HTR6MAPT
SCHEMBL5089907 0.79 HTR6 (0.44) TACR1HTR7HTR6ADRA2AADRA2B
SCHEMBL5095637 0.78 HTR6 (0.57) TACR1HTR7HTR6HTR1AHTR1B
SCHEMBL5093053 0.77 HTR6 (0.64) TACR1HTR7HTR6HTR1AHTR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7317035-B2 Tetracyclic arylcarbonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them SUVEN LIFE SCIENCES LIMITED (IN) 2008-01-08 — — US claimed
EP-1517909-B1 NOVEL TETRACYCLIC ARYLCARBONYL INDOLES HAVING SEROTONIN RECEPTOR AFFINITY USEFUL AS THERAPEUTIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SUVEN LIFE SCIENCES LTD (IN) 2006-10-25 — — EP claimed
US-20050250834-A1 Novel tetracyclic arylcarbonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical composition containing them SUVEN LIFE SCIENCES LIMITED (IN) 2005-11-10 — — US claimed
EP-1517909-A2 NOVEL TETRACYCLIC ARYLCARBONYL INDOLES HAVING SEROTONIN RECEPTOR AFFINITY USEFUL AS THERAPEUTIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Suven Life Sciences Limited (IN) 2005-03-30 — — EP claimed
WO-2004000205-A2 NOVEL TETRACYCLIC ARYLCARBONYL INDOLES HAVING SEROTONIN RECEPTOR AFFINITY USEFUL AS THERAPEUTIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SUVEN LIFE SCIENCES LIMITED (IN) 2003-12-31 — — WO claimed
US-7317035-B2 Tetracyclic arylcarbonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them SUVEN LIFE SCIENCES LIMITED (IN) 2008-01-08 — — US disclosed
EP-1517909-B1 NOVEL TETRACYCLIC ARYLCARBONYL INDOLES HAVING SEROTONIN RECEPTOR AFFINITY USEFUL AS THERAPEUTIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SUVEN LIFE SCIENCES LTD (IN) 2006-10-25 — — EP disclosed
US-20050250834-A1 Novel tetracyclic arylcarbonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical composition containing them SUVEN LIFE SCIENCES LIMITED (IN) 2005-11-10 — — US disclosed
EP-1517909-A2 NOVEL TETRACYCLIC ARYLCARBONYL INDOLES HAVING SEROTONIN RECEPTOR AFFINITY USEFUL AS THERAPEUTIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Suven Life Sciences Limited (IN) 2005-03-30 — — EP disclosed
WO-2004000205-A2 NOVEL TETRACYCLIC ARYLCARBONYL INDOLES HAVING SEROTONIN RECEPTOR AFFINITY USEFUL AS THERAPEUTIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SUVEN LIFE SCIENCES LIMITED (IN) 2003-12-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050250834-A1 Novel tetracyclic arylcarbonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical composition containing them TPH1, HTR1A, HTR5A HTR1A 2/4885ADRA2A 39/4885ADRA2B 32/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback